A real world study for Yi-Qi Huo-Xue prescription in the treatment of angina pectoris of coronary heart disease

Not Applicable

Recruiting

• Conditions: coronary heart disease

• Registration Number: ITMCTR2000002967
• Lead Sponsor: Oriental Hospital, Beijing University of Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Consistent with the diagnosis of coronary heart disease angina pectoris, with one of the following evidence:
(1) There is a clear history of old myocardial infarction;
(2) Coronary angiography, suggesting at least one coronary stenosis, and lumen stenosis >=50%;
(3) CTA suggested stenosis of the main vascular lumen >= 50% (or above moderate stenosis);
2. Angina pectoris attacks >=2 times per week;
3. Meet the diagnostic criteria of qi deficiency and blood stasis;
4. Aged 30-75 years;
5. Voluntarily sign the informed consent.

Exclusion Criteria

1. Coronary revascularization was performed within 60 days;
2. Use any preparation of traditional Chinese medicine (such as proprietary Chinese medicine, Chinese medicine granule, etc.) in the recent month;
3. Acute myocardial infarction occurred in recent month;
4. Patients with one of the following diseases:
(1) Patients with high blood pressure after hypertension and antihypertensive drug treatment (systolic blood pressure >= 180mmHg, diastolic blood pressure >=100mmHg);
(2) Severe arrhythmia (atrial fibrillation with rapid ventricular response, atrial flutter, paroxysmal ventricular tachycardia, etc.), pulmonary heart disease, rheumatic heart disease, myocarditis, cardiomyopathy, aortic dissection, pulmonary embolism and other serious diseases;
5. Chest pain symptoms related to hyperthyroidism, cervical spondylosis, gallbladder heart syndrome, gastroesophageal reflux disease or hiatal hernia, neurosis, climacteric syndrome, etc.;
6. The upper limit of serum alanine transaminase or serum creatinine >2 times the normal reference value.
7. Severe hematological diseases.
8. Malignant tumor;
9. Women of child-bearing age who are pregnant or breast-feeding or who are required to have children;
10. Mental illness or cognitive dysfunction;
11. Allergic to the test drug;
12. Have participated in other clinical trials within the recent month.

Study & Design

• Study Type: Observational study
• Study Design: Not specified